Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
403
Employees403
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
403
Employees403

NTLA Key Statistics

Market cap
1.62B
Market cap1.62B
Price-Earnings ratio
-3.43
Price-Earnings ratio-3.43
Dividend yield
Dividend yield
Average volume
7.57M
Average volume7.57M
High today
$14.70
High today$14.70
Low today
$13.65
Low today$13.65
Open price
$14.34
Open price$14.34
Volume
6.42M
Volume6.42M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$5.90
52 Week low$5.90

Stock Snapshot

The current Intellia Therapeutics(NTLA) stock price is $13.92, with a market capitalization of 1.62B. The stock trades at a price-to-earnings (P/E) ratio of -3.43.

As of 2026-01-26, Intellia Therapeutics(NTLA) stock has fluctuated between $13.65 and $14.70. The current price stands at $13.92, placing the stock +2.0% above today's low and -5.3% off the high.

The Intellia Therapeutics(NTLA)'s current trading volume is 6.42M, compared to an average daily volume of 7.57M.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.

NTLA News

Simply Wall St 3d
A Look At Intellia Therapeutics Valuation After Safety Concerns And HAE Market Uncertainty

Recent commentary on Intellia Therapeutics (NTLA) is focused on safety concerns and regulatory pauses in its transthyretin amyloidosis program, as well as quest...

A Look At Intellia Therapeutics Valuation After Safety Concerns And HAE Market Uncertainty
Simply Wall St 4d
Is ARK’s Buying Spree Reshaping Intellia Therapeutics’ Risk‑Reward Story Amid Clinical Uncertainty?

In recent days, Intellia Therapeutics has drawn fresh attention as ARK Invest extended a three-day buying streak in the stock, even as its ATTR program remains...

Is ARK’s Buying Spree Reshaping Intellia Therapeutics’ Risk‑Reward Story Amid Clinical Uncertainty?
Simply Wall St 6d
Is Intellia Therapeutics Pricing Make Sense After Sharp Rebound And DCF Upside Signals

Wondering whether Intellia Therapeutics at US$12.83 is offering value or just another volatile biotech story? This article walks through what the current price...

Is Intellia Therapeutics Pricing Make Sense After Sharp Rebound And DCF Upside Signals

Analyst ratings

48%

of 27 ratings
Buy
48.1%
Hold
44.4%
Sell
7.4%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.